PT2821416T - Anticorpo de recetor il-23 anti- humano inovador - Google Patents
Anticorpo de recetor il-23 anti- humano inovadorInfo
- Publication number
- PT2821416T PT2821416T PT13754932T PT13754932T PT2821416T PT 2821416 T PT2821416 T PT 2821416T PT 13754932 T PT13754932 T PT 13754932T PT 13754932 T PT13754932 T PT 13754932T PT 2821416 T PT2821416 T PT 2821416T
- Authority
- PT
- Portugal
- Prior art keywords
- human
- receptor antibody
- novel anti
- novel
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012040958 | 2012-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2821416T true PT2821416T (pt) | 2018-12-14 |
Family
ID=49082649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT13754932T PT2821416T (pt) | 2012-02-28 | 2013-02-27 | Anticorpo de recetor il-23 anti- humano inovador |
Country Status (7)
Country | Link |
---|---|
US (1) | US9371391B2 (pt) |
EP (1) | EP2821416B1 (pt) |
JP (1) | JP6137169B2 (pt) |
ES (1) | ES2701064T3 (pt) |
PL (1) | PL2821416T3 (pt) |
PT (1) | PT2821416T (pt) |
WO (1) | WO2013129454A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018204489A1 (en) * | 2017-05-02 | 2018-11-08 | Dana-Farber Cancer Institute, Inc. | Il-23r antagonists to reprogram intratumoral t regulatory cells into effector cells |
EP4416177A2 (en) | 2021-10-11 | 2024-08-21 | Y-Trap, Inc. | Compositions and methods that inhibit il-23 signaling |
CN113698484B (zh) * | 2021-10-13 | 2023-07-18 | 浙江博锐生物制药有限公司 | 抗il-23r抗体及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP0690132B1 (en) | 1993-03-11 | 2003-12-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-hiv monoclonal antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP2395025A1 (en) | 2007-02-28 | 2011-12-14 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
WO2010027767A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Engineered anti-il-23r antibodies |
CA2741566A1 (en) | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
TW201249867A (en) * | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
-
2013
- 2013-02-27 PT PT13754932T patent/PT2821416T/pt unknown
- 2013-02-27 EP EP13754932.5A patent/EP2821416B1/en active Active
- 2013-02-27 ES ES13754932T patent/ES2701064T3/es active Active
- 2013-02-27 US US14/381,268 patent/US9371391B2/en not_active Expired - Fee Related
- 2013-02-27 PL PL13754932T patent/PL2821416T3/pl unknown
- 2013-02-27 WO PCT/JP2013/055082 patent/WO2013129454A1/ja active Application Filing
- 2013-02-27 JP JP2014502301A patent/JP6137169B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2821416B1 (en) | 2018-10-03 |
PL2821416T3 (pl) | 2019-01-31 |
US20150126713A1 (en) | 2015-05-07 |
EP2821416A1 (en) | 2015-01-07 |
US9371391B2 (en) | 2016-06-21 |
WO2013129454A1 (ja) | 2013-09-06 |
JPWO2013129454A1 (ja) | 2015-07-30 |
EP2821416A4 (en) | 2015-06-17 |
ES2701064T3 (es) | 2019-02-20 |
JP6137169B2 (ja) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215267A1 (zh) | 嵌合抗原受體 | |
HK1213922A1 (zh) | 嵌合抗原受體 | |
EP2866833A4 (en) | CRYSTALLINE ANTIBODIES AGAINST HUMAN IL-23 | |
HK1210620A1 (en) | Multi-specific monoclonal antibodies | |
ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
EP2765193A4 (en) | CHIMERIC ANTIGEN RECEPTOR | |
EP2930240A4 (en) | ANTI-FOLR1 ANTIBODY | |
EP2832855A4 (en) | NEW ANTI-SIGLEC ANTIBODY-15 | |
EP2844290A4 (en) | NOVEL ANTIBODIES | |
ZA201407316B (en) | Anti-fgfr2 antibody | |
HK1223123A1 (zh) | 新穎抗人類 受體抗體 | |
EP2826790A4 (en) | GREMLIN-1 ANTIBODY | |
ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
PT2695897T (pt) | Novo anticorpo anti-receptor de il-23 humano | |
EP2804876A4 (en) | NEW ANTIBODIES | |
GB201220242D0 (en) | Antibody | |
EP2796550A4 (en) | NEW ANTIBODY ANTI CTGF HUMAN | |
EP2821416A4 (en) | NOVEL ANTIBODIES TO THE HUMAN IL-23 RECEPTOR | |
EP2848633A4 (en) | ANTI-CXADR ANTIBODY | |
EP2811018A4 (en) | ANTI-BODY ANTI-sAPPß |